Articles de revues : « Chronic stable angina »

1

Abrams, Jonathan. « Chronic Stable Angina ». New England Journal of Medicine 352, n^o 24 (16 juin 2005) : 2524–33. http://dx.doi.org/10.1056/nejmcp042317.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Ohman, E. Magnus. « Chronic Stable Angina ». New England Journal of Medicine 374, n^o 12 (24 mars 2016) : 1167–76. http://dx.doi.org/10.1056/nejmcp1502240.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

M Elshafae, Mohamed, Jehan H. Sabry, Mohamed A Salem et Hanan M Elshafee. « MicroRNA-155 in patients with Chronic Stable Angina ». Annals of Applied Bio-Sciences 4, n^o 1 (mars 2017) : A74—A82. http://dx.doi.org/10.21276/aabs.2017.1383.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

&NA;. « Chronic stable angina pectoris ». Inpharma Weekly &NA;, n^o 1193 (juin 1999) : 4. http://dx.doi.org/10.2165/00128413-199911930-00006.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Dalal, J. N., et A. C. Jain. « Chronic stable angina pectoris ». Postgraduate Medicine 91, n^o 4 (mars 1992) : 165–77. http://dx.doi.org/10.1080/00325481.1992.11701251.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Thadani, Udho, et Asim Chohan. « Chronic stable angina pectoris ». Postgraduate Medicine 98, n^o 6 (décembre 1995) : 175–88. http://dx.doi.org/10.1080/00325481.1995.11946093.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Higginbotham, Michael B., Kenneth G. Morris, R. Edward Coleman et Frederick R. Cobb. « Chronic stable angina monotherapy ». American Journal of Medicine 86, n^o 1 (janvier 1989) : 1–5. http://dx.doi.org/10.1016/0002-9343(89)90002-8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Jawad, Evyan, et Rohit Arora. « Chronic Stable Angina Pectoris ». Disease-a-Month 54, n^o 9 (septembre 2008) : 671–89. http://dx.doi.org/10.1016/j.disamonth.2008.06.009.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Berra, Kathy, Barbara Fletcher et Nancy Houston Miller. « Chronic stable angina : Addressing the needs of patients through risk reduction, education and support ». Clinical & ; Investigative Medicine 31, n^o 6 (1 décembre 2008) : 391. http://dx.doi.org/10.25011/cim.v31i6.4927.

Texte intégral

Résumé :

Chronic stable angina (CSA) is one of the most common symptoms experienced by persons with heart disease. CSA is defined by the physical symptoms resulting from blockage of blood flow through the coronary arteries. Anginal symptoms generally occur as a result of increased demands for blood flow, such as with physical activity, eating a large meal, emotional upset or exposure to cold weather. Symptoms vary widely and can include discomfort in the chest, arms, back and jaw, shortness of breath and a sense of increased fatigue. Many patients with chronic stable angina do not describe their symptoms as “pain” but have a sense of burning, tightness, pressure or heaviness in the chest and upper body. Chronic stable angina is usually relieved by stopping the activity that precipitated the symptoms, by resting, and by the use of Nitroglycerine. Anginal symptoms are called “chronic and stable” when they occur in a predictable fashion and are in response to “triggers” such as those mentioned above.

Styles APA, Harvard, Vancouver, ISO, etc.

10

&NA;. « Management of chronic stable angina ». Inpharma Weekly &NA;, n^o 1315 (novembre 2001) : 3. http://dx.doi.org/10.2165/00128413-200113150-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

BEATTIE, SALLY. « Management of Chronic Stable Angina ». Nurse Practitioner 24, n^o 5 (mai 1999) : 44???61. http://dx.doi.org/10.1097/00006205-199905000-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

O'Toole, L. « Chronic stable angina : treatment options ». BMJ 326, n^o 7400 (29 mai 2003) : 1185–88. http://dx.doi.org/10.1136/bmj.326.7400.1185.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Nash, David T., et Stephen D. Nash. « Ranolazine for chronic stable angina ». Lancet 372, n^o 9646 (octobre 2008) : 1335–41. http://dx.doi.org/10.1016/s0140-6736(08)61554-8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Gamham, S. P., K. Gunawardena, U. Hauf-Zacharlou et R. A. Blackwood. « Carvedilol in chronic stable angina. » Clinical Pharmacology & ; Therapeutics 59, n^o 2 (février 1996) : 163. http://dx.doi.org/10.1038/sj.clpt.1996.152.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Gupta, Prabha Nini, Praveen Velappan, Krishna Kumar Bhaskara Pillai et Riyas Abdul Salam. « Re chronic stable angina guidelines ». Indian Heart Journal 69, n^o 1 (janvier 2017) : 129–32. http://dx.doi.org/10.1016/j.ihj.2017.01.004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Walters, Michele Ann. « Management of Chronic Stable Angina ». Critical Care Nursing Clinics of North America 29, n^o 4 (décembre 2017) : 487–93. http://dx.doi.org/10.1016/j.cnc.2017.08.008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Padala, Santosh K., Michael P. Lavelle, Mandeep S. Sidhu, Katherine P. Cabral, Doralisa Morrone, William E. Boden et Peter P. Toth. « Antianginal Therapy for Stable Ischemic Heart Disease ». Journal of Cardiovascular Pharmacology and Therapeutics 22, n^o 6 (31 mars 2017) : 499–510. http://dx.doi.org/10.1177/1074248417698224.

Texte intégral

Résumé :

Chronic angina pectoris is associated with considerable morbidity and mortality, especially if treated suboptimally. For many patients, aggressive pharmacologic intervention is necessary in order to alleviate anginal symptoms. The optimal treatment of stable ischemic heart disease (SIHD) should be the prevention of angina and ischemia, with the goal of maximizing both quality and quantity of life. In addition to effective risk factor modification with lifestyle changes, intensive pharmacologic secondary prevention is the therapeutic cornerstone in managing patients with SIHD. Current guidelines recommend a multifaceted therapeutic approach with β-blockers as first-line treatment. Another important pharmacologic intervention for managing SIHD is nitrates. Nitrates can provide both relief of acute angina and can be used prophylactically before exposure to known triggers of myocardial ischemia to prevent angina. Additional therapeutic options include calcium channel blockers and ranolazine, an inhibitor of the late inward sodium current, that can be used alone or in addition to nitrates or β-blockers when these agents fail to alleviate symptoms. Ranolazine appears to be particularly effective for patients with microvascular angina and endothelial dysfunction. In addition, certain antianginal therapies are approved in Europe and have been shown to improve symptoms, including ivabradine, nicorandil, and trimetazidine; however, these have yet to be approved in the United States. Ultimately, there are several different medications available to the physician for managing the patient with SIHD having chronic angina, when either used alone or in combination. The purpose of this review is to highlight the most important therapeutic approaches to optimizing contemporary treatment in response to individual patient needs.

Styles APA, Harvard, Vancouver, ISO, etc.

18

Mesnier, Jules, Gregory Ducrocq, Nicolas Danchin, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Kim M. Fox et Philippe Gabriel Steg. « International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina : The Multinational CLARIFY Study ». Circulation 144, n^o 7 (17 août 2021) : 512–23. http://dx.doi.org/10.1161/circulationaha.121.054567.

Texte intégral

Résumé :

Background: Although angina is common in patients with stable coronary artery disease, limited data are available on its prevalence, natural evolution, and outcomes in the era of effective cardiovascular drugs and widespread use of coronary revascularization. Methods: Using data from 32 691 patients with stable coronary artery disease from the prospective observational CLARIFY registry (Prospective Observational Longitudinal Registry of Patients with Stable Coronary Artery Disease), anginal status was mapped each year in patients without new coronary revascularization or new myocardial infarction. The use of medical interventions in the year preceding angina resolution was explored. The effect of 1-year changes in angina status on 5-year outcomes was analyzed using multivariable analysis. Results: Among 7212 (22.1%) patients who reported angina at baseline, angina disappeared (without coronary revascularization) in 39.6% at 1 year, with further annual decreases. In patients without angina at baseline, 2.0% to 4.8% developed angina each year. During 5-year follow-up, angina was controlled in 7773 patients, in whom resolution of angina was obtained with increased use of antianginal treatment in 11.1%, with coronary revascularization in 4.5%, and without any changes in medication or revascularization in 84.4%. Compared to patients without angina at baseline and 1 year, persistence of angina and occurrence of angina at 1 year with conservative management were each independently associated with higher rates of cardiovascular death or myocardial infarction (adjusted hazard ratio, 1.32 [95% CI, 1.12−1.55] for persistence of angina; adjusted hazard ratio, 1.37 [95% CI, 1.11−1.70] for occurrence of angina) at 5 years. Patients whose angina had resolved at 1 year with conservative management were not at higher risk of cardiovascular death or myocardial infarction than those who never experienced angina (adjusted hazard ratio, 0.97 [95% CI, 0.82−1.15]). Conclusions: Angina affects almost one-quarter of patients with stable coronary artery disease but resolves without events or coronary revascularization in most patients. Resolution of angina within 1 year with conservative management predicted outcomes similar to lack of angina, whereas persistence or occurrence was associated with worse outcomes. Because most patients with angina are likely to experience resolution of symptoms, and because there is no demonstrated outcome benefit to routine revascularization, this study emphasizes the value of conservative management of stable coronary artery disease. Registration: URL: https://www.isrctn.com ; Unique identifier: ISRCTN43070564.

Styles APA, Harvard, Vancouver, ISO, etc.

19

Trujillo, Toby C., et Paul P. Dobesh. « Traditional Management of Chronic Stable Angina ». Pharmacotherapy 27, n^o 12 (décembre 2007) : 1677–92. http://dx.doi.org/10.1592/phco.27.12.1677.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Wee, Yong, Kylie Burns et Nicholas Bett. « Medical management of chronic stable angina ». Australian Prescriber 38, n^o 4 (1 août 2015) : 131–36. http://dx.doi.org/10.18773/austprescr.2015.042.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Staniforth, Andrew D. « Contemporary Management of Chronic Stable Angina ». Drugs & ; Aging 18, n^o 2 (2001) : 109–21. http://dx.doi.org/10.2165/00002512-200118020-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

&NA;. « Nicorandil beneficial in chronic stable angina ». Inpharma Weekly &NA;, n^o 1334 (avril 2002) : 14. http://dx.doi.org/10.2165/00128413-200213340-00027.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

&NA;. « Arginine beneficial in chronic stable angina ? » Inpharma Weekly &NA;, n^o 1326 (février 2002) : 13. http://dx.doi.org/10.2165/00128413-200213260-00029.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Wong, John B. « Myocardial Revascularization for Chronic Stable Angina ». Annals of Internal Medicine 113, n^o 11 (1 décembre 1990) : 852. http://dx.doi.org/10.7326/0003-4819-113-11-852.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Kaski, Juan-Carlos, Antonio Arrebola-Moreno et Jason Dungu. « Treatment strategies for chronic stable angina ». Expert Opinion on Pharmacotherapy 12, n^o 18 (18 novembre 2011) : 2833–44. http://dx.doi.org/10.1517/14656566.2011.634799.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Messenger, John C., et John D. Carroll. « Outpatient Management of Chronic Stable Angina ». Primary Care Case Reviews 1, n^o 4 (décembre 1998) : 168–80. http://dx.doi.org/10.1097/00129300-199801040-00003.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Dixit, Deepali, et Katarzyna Kimborowicz. « Pharmacologic management of chronic stable angina ». Journal of the American Academy of Physician Assistants 28, n^o 6 (juin 2015) : 1–8. http://dx.doi.org/10.1097/01.jaa.0000465223.98395.45.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Richard, C. « Refractory chronic stable angina-now what ? » Clinical Cardiology 27, n^o 7 (juillet 2004) : 375–76. http://dx.doi.org/10.1002/clc.4960270701.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Reichek, Nathaniel. « Nitroglycerin in chronic stable angina pectoris ». American Journal of Cardiology 60, n^o 15 (novembre 1987) : H15—H17. http://dx.doi.org/10.1016/0002-9149(87)90545-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Myers, G. Robert, et William S. Weintraub. « Medical therapies for chronic stable angina ». Current Cardiovascular Risk Reports 2, n^o 5 (septembre 2008) : 350–58. http://dx.doi.org/10.1007/s12170-008-0063-7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Gorlin, Richard. « Treatment of chronic stable angina pectoris ». American Journal of Cardiology 70, n^o 17 (novembre 1992) : G26—G31. http://dx.doi.org/10.1016/0002-9149(92)90022-q.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Vadnais, David S., et Nanette K. Wenger. « Management Options in Chronic Stable Angina Pectoris : Focus on Ranolazine ». Clinical Medicine. Therapeutics 1 (janvier 2009) : CMT.S2214. http://dx.doi.org/10.4137/cmt.s2214.

Texte intégral

Résumé :

Chronic stable angina pectoris results from a fixed coronary arterial obstruction causing an imbalance between myocardial oxygen supply and demand. Current therapy aims to reduce cardiovascular events (vasculoprotective) thereby improving survival, and/or relieve ischemic symptoms (antianginal) thereby improving the quality of life. Vasculoprotective therapy consists of lifestyle modification, antiplatelet agents, lipid lowering therapy and angiotensin-converting enzyme (ACE) inhibitors. Conventional antianginal therapy for patients with chronic stable angina consists of beta-blockers, calcium channel blockers and nitrates, with surgical or percutaneous revascularization serving an adjunctive role. Despite the investigation of multiple novel therapies and medications over the past 25 years, arguably the most significant contribution to antianginal therapy during that time involved the recent introduction of ranolazine. Ranolazine acts via a distinctive pathway, inhibiting the late sodium current of the action potential in ischemic myocytes. Multiple studies have demonstrated that ranolazine significantly reduces anginal symptoms and improves exercise performance in patients with chronic stable angina but does not reduce mortality. Ranolazine does not affect either heart rate or blood pressure, a unique property among the current antianginal agents. Despite its QT prolongation, ranolazine has a proven safety profile and is not proarrhythmic. In fact, in a recent large randomized trial, ranolazine reduced the incidence of supraventricular tachycardia, ventricular tachycardia, new-onset atrial fibrillation and bradycardic events. Ranolazine may confer some additional benefits such as a reduction in HbA1c levels and improved left ventricular diastolic function. Ranolazine is now approved for use in chronic stable angina. Current guidelines recommend beta-blockers as the first line antianginal agent due to the proven mortality reduction. However, for patients with bradycardia or hypotension, ranolazine may be considered as initial antianginal therapy.

Styles APA, Harvard, Vancouver, ISO, etc.

33

Galderisi, M., A. Celentano, G. Mossetti, M. Garofalo, G. F. Mureddu, P. Tammaro, E. Gravina et O. de Divitiis. « Effects of Nicardipine on Chronic Stable Effort Angina : a Non-Invasive Assessment ». Journal of International Medical Research 16, n^o 5 (septembre 1988) : 349–58. http://dx.doi.org/10.1177/030006058801600504.

Texte intégral

Résumé :

The effects of 60 mg/day nicardipine hydrochloride were evaluated in a 4-week single-blind study on 12 patients with chronic stable effort angina. All patients completed the treatment with few reports of adverse effects. Nicardipine hydrochloride was effective in reducing the incidence of anginal attacks and consumption of glyceryl trinitrate. Treadmill exercise time, angina onset time and the time to 1 mm ST-segment depression were increased. The extent of ST-segment depression was reduced at maximum comparable exercise, with a reduced rate–pressure product and, at maximum exercise, with an increased rate–pressure product. Myocardial stress 201Tl scintillography was carried out in eight of the patients and showed improved washout in antero-septal, infero-apical and postero-lateral segments. Echocardiographic measures of left ventricular function were enhanced because of reduction of afterload. Systemic vascular resistance and end-systolic stress were also decreased and a significant correlation was found between the increase in ejection fraction and reduction of systolic blood pressure. It is concluded that nicardipine hydrochloride is effective in the control of stable effort angina by reducing myocardial oxygen consumption and enhancing coronary blood flow thereby improving left ventricular function.

Styles APA, Harvard, Vancouver, ISO, etc.

34

Tarkin, Jason M., et Juan Carlos Kaski. « Pharmacological treatment of chronic stable angina pectoris ». Clinical Medicine 13, n^o 1 (février 2013) : 63–70. http://dx.doi.org/10.7861/clinmedicine.13-1-63.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Maseri, A. « Medical therapy of chronic stable angina pectoris. » Circulation 82, n^o 6 (décembre 1990) : 2258–62. http://dx.doi.org/10.1161/01.cir.82.6.2258.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Thadani, Udho. « Current Medical Management of Chronic Stable Angina ». Journal of Cardiovascular Pharmacology and Therapeutics 9, n^o 1_suppl (mars 2004) : S11—S29. http://dx.doi.org/10.1177/107424840400900103.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Toutouzas, Konstantinos, Antonis Karanasos, Maria Drakopoulou, Eleutherios Tsiamis, Andreas Synetos, Stamatios Lerakis, Christodoulos Stefanadis et Stamatios Lerakis. « Percutaneous Coronary Intervention in Chronic Stable Angina ». American Journal of the Medical Sciences 339, n^o 6 (juin 2010) : 568–72. http://dx.doi.org/10.1097/maj.0b013e3181d673d7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Staniforth, Andrew D. « Evidence based treatment of chronic stable angina ». International Journal of Cardiology 63, n^o 1 (janvier 1998) : 21–25. http://dx.doi.org/10.1016/s0167-5273(97)00286-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Bundy, Christine, Douglas Carroll, Louise Wallace et Robert Nagle. « Psychological treatment of chronic stable angina pectoris ». Psychology & ; Health 10, n^o 1 (décembre 1994) : 69–77. http://dx.doi.org/10.1080/08870449408401937.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Holmes, David R., Bernard J. Gersh, Patrick Whitlow, Spencer B. King et James T. Dove. « Percutaneous Coronary Intervention for Chronic Stable Angina ». JACC : Cardiovascular Interventions 1, n^o 1 (février 2008) : 34–43. http://dx.doi.org/10.1016/j.jcin.2007.10.001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Krikler, Dennis M. « Calcium antagonists for chronic stable angina pectoris ». American Journal of Cardiology 59, n^o 3 (janvier 1987) : B95—B100. http://dx.doi.org/10.1016/0002-9149(87)90088-9.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

Friedewald, Vincent E., Spencer B. King, Carl J. Pepine, George W. Vetrovec et William C. Roberts. « The Editor’s Roundtable : Chronic Stable Angina Pectoris ». American Journal of Cardiology 100, n^o 11 (décembre 2007) : 1635–43. http://dx.doi.org/10.1016/j.amjcard.2007.09.001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

O'Rourke, Robert A. « Cost-effective management of chronic stable angina ». Clinical Cardiology 19, n^o 6 (juin 1996) : 497–501. http://dx.doi.org/10.1002/clc.4960190611.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

Richard Conti, C. « Medical device therapy for chronic stable angina ». Clinical Cardiology 21, n^o 2 (février 1998) : 71. http://dx.doi.org/10.1002/clc.4960210202.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

Aldakkak, Mohammed, David F. Stowe et Amadou K. S. Camara. « Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris ». Clinical Medicine Insights : Therapeutics 5 (janvier 2013) : CMT.S7824. http://dx.doi.org/10.4137/cmt.s7824.

Texte intégral

Résumé :

Coronary heart disease is a global malady and it is the leading cause of death in the United States. Chronic stable angina is the most common manifestation of coronary heart disease and it results from the imbalance between myocardial oxygen supply and demand due to reduction in coronary blood flow. Therefore, in addition to lifestyle changes, commonly used pharmaceutical treatments for angina (nitrates, β-blockers, Ca2+ channel blockers) are aimed at increasing blood flow or decreasing O2 demand. However, patients may continue to experience symptoms of angina. Ranolazine is a relatively new drug with anti-anginal and anti-arrhythmic effects. Its anti-anginal mechanism is not clearly understood but the general consensus is that ranolazine brings about its anti-anginal effects by inhibiting the late Na+ current and the subsequent intracellular Ca2+ accumulation. Recent studies suggest other effects of ranolazine that may explain its anti-anginal and anti-arrhythmic effects. Nonetheless, clinical trials have proven the efficacy of ranolazine in treating chronic angina. It has been shown to be ineffective, however, in treating acute coronary syndrome patients. Ranolazine is a safe drug with minimal side effects. It is metabolized mainly in the liver and cleared by the kidney. Therefore, caution must be taken in patients with impaired hepatic or renal function. Due to its efficacy and safety, ranolazine was approved for the treatment of chronic angina by the Food and Drug Administration (FDA) in 2006.

Styles APA, Harvard, Vancouver, ISO, etc.

46

Arora, Rohit. « Utility of ranolazine in chronic stable angina patients ». Vascular Health and Risk Management Volume 4 (août 2008) : 819–24. http://dx.doi.org/10.2147/vhrm.s2841.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

&NA;. « Lercanidipine 'safe' in patients with chronic stable angina ». Reactions Weekly &NA;, n^o 850 (mai 2001) : 4. http://dx.doi.org/10.2165/00128415-200108500-00006.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Jackson, Janet Marianne. « Ivabradine – a novel treatment for chronic stable angina ». Drugs in Context 4 (2008) : 1–18. http://dx.doi.org/10.7573/dic.212225.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Norton, Catherine, Vasiliki Georgiopoulou, Andreas Kalogeropoulos et Javed Butler. « Chronic stable angina : pathophysiology and innovations in treatment ». Journal of Cardiovascular Medicine 12, n^o 3 (mars 2011) : 218–19. http://dx.doi.org/10.2459/jcm.0b013e328343e974.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Zerumsky, Kristin, et Brian F. McBride. « Ranolazine in the management of chronic stable angina ». American Journal of Health-System Pharmacy 63, n^o 23 (1 décembre 2006) : 2331–38. http://dx.doi.org/10.2146/ajhp060042.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Articles de revues sur le sujet « Chronic stable angina »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres